|本期目录/Table of Contents|

[1]孙晓宇 张志宏 张昌文.膀胱癌类器官模型的研究进展[J].天津医科大学学报,2023,29(05):564-567.
点击复制

膀胱癌类器官模型的研究进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
29卷
期数:
2023年05期
页码:
564-567
栏目:
综述
出版日期:
2023-09-20

文章信息/Info

Title:
-
文章编号:
1006-8147（2023）05-0564-04
作者:
孙晓宇 张志宏 张昌文
（天津医科大学第二医院泌尿外科，天津300211）
Author(s):
-
关键词:
类器官; 膀胱癌; 肿瘤研究; 3D肿瘤模型
Keywords:
-
分类号:
R694
DOI:
-
文献标志码:
A
摘要:
膀胱癌（BC）是泌尿外科常见恶性肿瘤之一，患者术后5年生存率较低。近年来，新兴的三维类器官模型在抗肿瘤药物筛选和疾病机制探索等方面为膀胱癌研究带来了极大推动。本文对膀胱癌类器官模型的建立、应用、面临的挑战进行了综述，并对未来应用进行了展望。
Abstract:
-

参考文献/References:

[1] BABJUK M，BURGER M，CAPOUN O，et al. European association of urology guidelines on non-muscle-invasive bladder cancer（ta，t1，and carcinoma in situ）[J]. Eur Urol，2022，81（1）：75-94.
[2] ALFRED WITJES J，LEBRET T，COMPRAT E M，et al. Updated 2016 eau guidelines on muscle-invasive and metastatic bladder cancer[J]. Eur Urol，2017，71（3）：462-475.
[3] LANCASTER M A，KNOBLICH J A. Organogenesis in a dish：modeling development and disease using organoid technologies[J]. Science，2014，345（6194）：1247125.
[4] DROST J，CLEVERS H. Organoids in cancer research[J]. Nat Rev Cancer，2018，18（7）：407-418.
[5] LI M，IZPISUA BELMONTE J C. Organoids-preclinical models of human disease[J]. N Engl J Med，2019，380（6）：569-579.
[6] JACOB F，SALINAS R D，ZHANG D Y，et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter-and intra-tumoral heterogeneity[J]. Cell，2020，180（1）：188-204.e22.
[7] SATO T，VRIES R G，SNIPPERT H J，et al. Single lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche[J]. Nature，2009，459（7244）：262-265.
[8] BARTFELD S，BAYRAM T，VAN DE WETERING M，et al. In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection[J]. Gastroenterology，2015，148（1）：126-136.e6.
[9] DIAO J，LIU J，WANG S，et al. Sweat gland organoids contribute to cutaneous wound healing and sweat gland regeneration[J]. Cell Death Dis，2019，10（3）：238.
[10] LANCASTER M A，RENNER M，MARTIN C A，et al. Cerebral organoids model human brain development and microcephaly[J]. Nature，2013，501（7467）：373-379.
[11] SACHS N，DE LIGT J，KOPPER O，et al. A living biobank of breast cancer organoids captures disease heterogeneity[J]. Cell，2018，172（1-2）：373-386.e10.
[12] LEE S H，HU W，MATULAY J T，et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer[J]. Cell，2018，173（2）：515-528.e17.
[13] OOKI A，VANDENBUSSCHE C J，KATES M，et al. Cd24 regulates cancer stem cell（csc）-like traits and a panel of csc-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer[J]. Br J Cancer，2018，119（8）：961-970.
[14] KITA Y，HAMADA A，SAITO R，et al. Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer：a summary of preclinical studies[J]. Br J Cancer，2019，121（12）：1027-1038.
[15] AMARAL R，ZIMMERMANN M，MA A-H，et al. A simple three-dimensional in vitro culture mimicking the in vivo-like cell behavior of bladder patient-derived xenograft models[J]. Cancers（Basel），2020，12（5）：1304.
[16] MURAKAMI K，KITA Y，SAKATANI T，et al. Antitumor effect of wee1 blockade as monotherapy or in combination with cisplatin in urothelial cancer[J]. 2021，112（9）：3669-3681.
[17] CAI E Y，GARCIA J，LIU Y，et al. A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture[J]. Sci Rep，2021，11（1）：4609.
[18] VLAAR J M，BORGMAN A，KALKHOVEN E，et al. Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer[J]. Sci Rep，2022，12（1）：10081.
[19] RANGSITRATKUL C，LAWSON C，BERNIER-GODON F，et al. Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer[J]. Mol Ther Oncolytics，2022，24：507-521.
[20] MULLENDERS J，DE JONGH E，BROUSALI A，et al. Mouse and human urothelial cancer organoids：a tool for bladder cancer research[J]. Proc Natl Acad Sci U S A，2019，116（10）：4567-4574.
[21] YOSHIDA T，SOPKO N A，KATES M，et al. Three-dimensional organoid culture reveals involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells[J]. Oncotarget，2018，9（13）：11060-11070.
[22] KIM E，CHOI S，KANG B，et al. Creation of bladder assembloids mimicking tissue regeneration and cancer[J]. Nature，2020，588（7839）：664-669.
[23] WHYARD T，LIU J，DARRAS F S，et al. Organoid model of urothelial cancer：establishment and applications for bladder cancer research[J]. Biotechniques，2020，69（3）：193-199.
[24] NAMEKAWA T，IKEDA K，HORIE-INOUE K，et al. ALDH1A1 in patient-derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression[J]. Int J Cancer，2020，146（4）：1099-1113.
[25] YOON W H，LEE H-R，KIM S，et al. Use of inkjet-printed single cells to quantify intratumoral heterogeneity[J]. Biofabrication，2020， 12（3）：035030.
[26] YU L，LI Z，MEI H，et al. Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells[J]. Clin Transl Immunology，2021，10（2）：e1248.
[27] SHEN L，ZHANG J，ZHENG Z，et al. Phgdh inhibits ferroptosis and promotes malignant progression by upregulating slc7a11 in bladder cancer[J]. Int J Biol Sci，2022，18（14）：5459-5474.
[28] WEI Y，AMEND B，TODENH?魻FER T，et al. Urinary tract tumor organoids reveal eminent differences in drug sensitivities when compared to 2-dimensional culture systems[J]. Int J Mol Sci，2022，23（11）：6305.
[29] WANG M，CHEN X，TAN P，et al. Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer[J]. Cancer Cell，2022，40（9）：1044-1059.
[30] NEAL J T，LI X，ZHU J，et al. Organoid modeling of the tumor immune microenvironment[J]. Cell，2018，175（7）：1972-1988.
[31] YIN S，XI R，WU A，et al. Patient-derived tumor-like cell clusters for drug testing in cancer therapy[J]. Sci Transl Med，2020，12（549）：eaaz1723.
[32] GHEIBI P，ZENG S，SON K J，et al. Microchamber cultures of bladder cancer：a platform for characterizing drug responsiveness and resistance in pdx and primary cancer cells[J]. Sci Rep，2017，7（1）：12277.
[33] 罗升昌，王颖，王士斌，等. 基于微流控技术构建3D肿瘤模型用于药物筛选 [J]. 科学通报，2021，66（34）：4395-4410.
[34] SEREX L，SHARMA K，RIZOV V，et al. Microfluidic-assisted bioprinting of tissues and organoids at high cell concentrations[J]. Biofabrication，2021，13（2）：10.1088/1758-5090.
[35] YUKI K，CHENG N，NAKANO M，et al. Organoid models of tumor immunology[J]. Trends immunol，2020，41（8）：652-664.
[36] GAO D，VELA I，SBONER A，et al. Organoid cultures derived from patients with advanced prostate cancer[J]. Cell，2014，159（1）：176-187.
[37] DROST J，KARTHAUS W R，GAO D，et al. Organoid culture systems for prostate epithelial and cancer tissue[J]. Nat Protoc，2016， 11（2）：347-358.
[38] 赵冰，宋伟，王海霞. 肿瘤类器官诊治平台的质量控制标准中国专家共识（2022年版）[J]. 中国癌症杂志，2022，32（07）：657-668.
[39] 王树滨，高静，朱宇，等. 类器官药物敏感性检测指导肿瘤精准治疗临床应用专家共识（2022年版）[J]. 中国癌症防治杂志，2022， 14（03）：234-239.
[40] RINGQUIST R，GHOSHAL D，JAIN R，et al. Understanding and improving cellular immunotherapies against cancer：from cell-manufacturing to tumor-immune models[J]. Adv Drug Deliv Rev，2021，179：114003.
[41] FORSYTHE S D，ERALI R A，SASIKUMAR S，et al. Organoid platform in preclinical investigation of personalized immunotherapy efficacy in appendiceal cancer：feasibility study[J]. Clin Cancer Res，2021，27（18）：5141-5150.
[42] CARROLL J A，FOLIAKI S T，HAIGH C L. A 3D cell culture approach for studying neuroinflammation[J]. J Neurosci Methods，2021，358：109201.
[43] KASSIS T，HERNANDEZ-GORDILLO V，LANGER R，et al. Orgaquant：human intestinal organoid localization and quantification using deep convolutional neural networks[J]. Sci Rep，2019，9（1）：12479.
[44] BUENROSTRO J D，GIRESI P G，ZABA L C，et al. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin，DNA-binding proteins and nucleosome position[J]. Nat Methods，2013，10（12）：1213-1218.
[45] LIANG Z，LI G，WANG Z，et al. BL-Hi-C is an efficient and sensitive approach for capturing structural and regulatory chromatin interactions[J]. Nat Commun，2017，8（1）：1622.

相似文献/References:

[1]陈可新,郝晓东,薄志强,等.≤pT2N0M0膀胱癌根治术后近期复发的影响因素分析[J].天津医科大学学报,2017,23(04):357.
　CHEN Ke-xin,HAO Xiao-dong,BO Zhi-qiang,et al.Influencing factors and prognosis of short-term relapse after radical cystectomy of primary bladder cancer（≤pT2N0M0）[J].Journal of Tianjin Medical University,2017,23(05):357.
[2]孟旭英,李珍瑾,郭剑超.组蛋白甲基转移酶EZH2抑制剂联合抗癌药物对膀胱癌细胞功能影响的研究[J].天津医科大学学报,2018,24(01):25.
　MENG Xu-ying,LI Zhen-jin,GUO Jian-chao.Effect of histone methyltransferase EZH2 inhibitor combined with anticancer drugs on migration and proliferation of bladder cancer cells[J].Journal of Tianjin Medical University,2018,24(05):25.
[3]刘 莉 康家旗 综 述,刘晓强 审 校.膀胱癌外周血生物标志物研究进展[J].天津医科大学学报,2018,24(06):566.
[4]刘志飞,张志宏,邢力永,等.RRM1 mRNA与吉西他滨药物膀胱灌注治疗膀胱癌疗效的关系[J].天津医科大学学报,2019,25(01):51.
　LIU Zhi-fei,ZHANG Zhi-hong,XING Li-yong,et al.The relationship between expression of RRM1 mRNA and efficacy of intravesical of gemcitabine in patients with nonmuscle-insive bladder caner[J].Journal of Tianjin Medical University,2019,25(05):51.
[5]付真睿,盛 飞,张昌文,等.SOX6在膀胱癌发生发展中的作用及相关机制[J].天津医科大学学报,2019,25(04):373.
　FU Zhen-rui,SHENG Fei,ZHANG Chang-wen,et al.The characteristics of SOX6 in development of bladder cancer and relevant mechanism[J].Journal of Tianjin Medical University,2019,25(05):373.
[6]王银蕾,杨 瀚,高 杰,等.PITX2启动子甲基化及其与膀胱癌临床病理的关系[J].天津医科大学学报,2020,26(01):39.
　WANG Yin-lei,YANG Han,GAO Jie,et al.Methylation of PITX2 promoter and relationship with clinical pathology of bladder cancer[J].Journal of Tianjin Medical University,2020,26(05):39.
[7]王玉杰,沈冲,高深,等.长链非编码RNA-FENDRR在膀胱癌组织中的表达及临床意义[J].天津医科大学学报,2020,26(05):445.
　WANG Yu-jie,SHEN Chong,GAO Shen,et al.Expression of long non-coding RNA FENDRR in human bladder cancer tissues and Clinical significance[J].Journal of Tianjin Medical University,2020,26(05):445.
[8]朱建强,郑志文,付青峰,等.人工纳米材料在膀胱癌诊疗中的研究进展[J].天津医科大学学报,2022,28(05):563.
[9]陆益,于佳熙,梁政.氯丙嗪对膀胱癌BT-B细胞迁移功能的影响[J].天津医科大学学报,2022,28(06):621.
　LU Yi,YU Jia-xi,LIANG Zheng.The effect of chlorpromazine on the migration of BT-B cellsin bladder cancer[J].Journal of Tianjin Medical University,2022,28(05):621.
[10]朱 亮,陈业刚.基于失巢凋亡相关标志物预测膀胱癌患者预后[J].天津医科大学学报,2024,30(01):56.[doi:10.20135/j.issn.1006-8147.2024.01.0056]
　ZHU Liang,CHEN Yegang.Prognosis of patients with bladder cancer predicted by biomarker associated with anoikis[J].Journal of Tianjin Medical University,2024,30(05):56.[doi:10.20135/j.issn.1006-8147.2024.01.0056]

备注/Memo

备注/Memo:
基金项目 国家重点研发计划项目（2021YFC2009303）
作者简介 孙晓宇（1995-），男，博士在读，研究方向：泌尿肿瘤疾病; 通信作者：张昌文，E-mail：zhangchangwen05@163.com。
更新日期/Last Update: 2023-09-25